Hengrui Yuanzheng (Shanghai) Biotechnology

Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd. is a biopharmaceutical company founded in 2015, specializing in the development of precision medicines and immunotherapy products for solid tumors. The company was established as a joint venture between Jiangsu Hengrui Pharmaceuticals Group and Shenzhen Yuanzheng Cell. The company is headquartered in Shanghai, with wholly-owned subsidiaries and cell therapy research centers in Shenzhen and Guangzhou.

The company's core technology is the Multiple Antigen Specific Cell Therapy (MASCT), described as a fourth-generation tumor autologous immune cell therapy technique. Their primary product, the multi-antigen autologous immune cell injection (MASCT-I), has received approval for clinical trials from the National Medical Products Administration of China and is currently in Phase II trials for treating advanced soft tissue sarcoma. Hengrui Yuanzheng's product pipeline also includes TCR-T immune cell products and TCR bispecific antibody products. The company focuses on developing treatments for a variety of cancers, including melanoma, non-small cell lung cancer, breast cancer, colorectal cancer, and soft tissue sarcomas.

Hengrui Yuanzheng has secured multiple rounds of funding, including a Series A, and subsequent B, C, and C++ rounds with investments from firms like Green Pine Capital Partners, Sincere VC, and CICC Capital. The company has a team of nearly 100 professionals dedicated to the research, development, and production of its innovative drugs. The chairman of the parent company, Hengrui Pharma, is Sun Piaoyang. The legal representative of Hengrui Yuanzheng is Li Kejian.

Keywords: immunotherapy, solid tumors, cell therapy, precision medicine, oncology, MASCT, TCR-T, biopharmaceutical, clinical trials, cancer treatment